Actuate Therapeutics Past Earnings Performance
Past criteria checks 0/6
Actuate Therapeutics's earnings have been declining at an average annual rate of -30.4%, while the Biotechs industry saw earnings growing at 15.5% annually.
Key information
-30.4%
Earnings growth rate
-11.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Actuate Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -28 | 3 | 24 |
31 Dec 23 | 0 | -25 | 3 | 22 |
Quality Earnings: ACTU is currently unprofitable.
Growing Profit Margin: ACTU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if ACTU's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare ACTU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACTU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.8%).
Return on Equity
High ROE: ACTU's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.